• 1
    Jeannet M, Pinn VW, Flax MH, Winn HJ, Russell PS. Humoral antibodies in renal allotransplantation in man. N Engl J Med 1970; 282: 111117.
  • 2
    Halloran PF. The clinical importance of alloantibody-mediated rejection. Am J Transpl 2003; 3: 639640.
  • 3
    Halloran PF, Wadgymar A, Ritchie S, Falk J, Solez K, Srinivasa NS. The significance of anti-class I antibody response. Clinical and pathologic features of anti-class I mediated rejection. Transplantation 1990; 49: 8591.
  • 4
    Halloran PF, Schlaut J, Solez K, Srinivasa NS. The significance of anti-class I antibody response. II. Clinical and pathologic features of renal transplants with anti-class I-like antibody. Transplantation 1992; 53: 550555.
  • 5
    Trpkov K, Campbell P, Pazderka F, Cockfield S, Solez K, Halloran PF. Pathologic features of acute renal allograft rejection associated with donor-specific antibody. Transplantation 1996; 61: 15861592.
  • 6
    Feucht HE, Schneeberger H, Hillebrand G et al. Capillary deposition of C4d complement fragment and early graft loss. Kidney Int 1993; 43: 13331338.
  • 7
    Pascual M, Saidman S, Tolkoff-Rubin N et al. Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. Transplantation 1998; 66: 14601464.
  • 8
    Collins AB, Schneeberger E, Pascual M et al. Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol 1999; 10: 22082214.
  • 9
    Crespo M, Pascual M, Tolkoff-Rubin N et al. Acute humoral rejection in renal allograft recipients: Incidence, serology and clinical characteristics. Transplantation 2001; 71: 652658.
  • 10
    Böhmig GA, Exner M, Habicht A et al. Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol 2002; 13: 10911009.
  • 11
    Vongwiwatana A, Tasanarong A, Hidalgo LG, Halloran PF. The role of B cells and alloantibody in the host response to human organ allografts. Immunol Rev 2003; 196: 197218.
  • 12
    Böhmig GA, Regele H, Exner M et al. C4d-positive acute humoral renal allograft rejection: effective treatment by immunoadsorption. J Am Soc Nephrol 2001; 12: 24822489.
  • 13
    Regele H, Böhmig GA, Habicht A et al. Capillary deposition of complement split product C4d in renal allograft is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 2002; 13: 23712380.
  • 14
    Lederer SR, Kluth-Pepper B, Schneeberger H, Albert E, Land W, Feucht HE. Impact of humoral alloreactivity early after transplantation on the long-term survival of renal allografts. Kidney Int 2001; 59: 334341.
  • 15
    Herzenberg AM, Gill JS, Djurdjev O, Magil AB. C4d deposition in acute rejection: an independent long-term prognostic factor. J Am Soc Nephrol 2002; 13: 234241.
  • 16
    Thurman JM, Lucia MS, Ljubanovic D, Holers VM. Acute tubular necrosis is characterized by activation of the alternative pathway of complement. Kidney Int 2005; 67: 524530.
  • 17
    Haas M, Ratner LE, Montgomery RA. C4d staining of perioperative renal transplant biopsies. Transplantation 2002; 74: 711717.
  • 18
    Racusen LC, Halloran PF, Solez K. Banff 2003 meeting report: new diagnostic insights and standards. Am J Transplant 2004; 4: 15621566.
  • 19
    Regele H, Exner M, Watschinger B et al. Endothelial C4d deposition is associated with inferior kidney allograft outcome independently of cellular rejection. Nephrol Dial Transplant 2001; 16: 20582066.
  • 20
    Mauiyyedi S, Crespo M, Collins AB et al. Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology and pathologic classification. J Am Soc Nephrol 2002; 13: 779787.
  • 21
    Shah A, Nadasdy T, Arend L et al. Treatment of C4d-positive acute humoral rejection with plasmapheresis and rabbit polyclonal antithymocyte globulin. Transplantation 2004; 77: 13991405.
  • 22
    Rocha PN, Butterly DW, Greenberg A et al. Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation 2003; 75: 14901495.
  • 23
    White NB, Greenstein SM, Cantafio AW et al. Successful rescue therapy with plasmapheresis and intravenous immunoglobulin for acute humoral renal transplant rejection. Transplantation 2004; 78: 772774.
  • 24
    Min L, Shuming J, Zheng T et al. Novel rescue therapy for C4d-positive acute humoral renal allograft rejection. Clin Transplant 2005; 19: 5155.
  • 25
    Feucht HE, Opelz G. The humoral immune response towards HLA class II determinants in renal transplantation. Kidney Int 1996; 50: 14641475.
  • 26
    Karpinski M, Rush D, Jeffery J et al. Flow cytometric crossmatching in primary renal transplant recipients with a negative anti-human globulin enhanced cytotoxicity crossmatch. J Am Soc Nephrol 2001; 12: 28072814.
  • 27
    Nickeleit V, Zeiler M, Gudat F, Thiel G, Mihatsch MJ. Detection of the complement degradation product C4d in renal allografts: diagnostic and therapeutic implications. J Am Soc Nephrol 2002; 13: 242251.
  • 28
    Montgomery RA, Zachary AA, Racusen LC et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match positive recipients. Transplantation 2000; 70: 887895.
  • 29
    Baid S, Saidman SL, Tolkoff-Rubin N et al. Managing the highly sensitized transplant recipient and B cell tolerance. Curr Opin Immunol 2001; 13: 577581.
  • 30
    Jordan SC, Quartel AS, Czer LS et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 1998; 66: 800805.
  • 31
    Glotz D, Antoine C, Julia P et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2002; 2: 758760.
  • 32
    Jordan SC, Tyan D, Stablein D et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004; 15: 32563262.
  • 33
    Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346: 580590.
  • 34
    Halloran PF, Melk A, Barth C. Rethinking chronic allograft nephropathy: the concept of accelerated senescence. J Am Soc Nephrol 1999; 10: 167181.
  • 35
    Ivanyi B, Fahmy H, Brown H, Szenohradszky P, Halloran PF, Solez K. Peritubular capillaries in chronic renal allograft rejection: a quantitative ultrastructural study. Hum Pathol 2000; 31: 11291138.
  • 36
    Vongwiwatana A, Gourishankar S, Campbell PM, Solez K, Halloran PF Peritubular capillary changes and C4d deposits are associated with transplant glomerulopathy but not IgA nephropathy. Am J Transplant 2004; 4: 124129.
  • 37
    Theruvath TP, Saidman SL, Mauiyyedi S et al. Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection. Transplantation 2001; 72: 7783.
  • 38
    Mauiyyedi S, Pelle P, Saidman S et al. Chronic humoral rejection: identification of antibody mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 2001; 12: 574582.
  • 39
    Cardarelli F, Pascual M, Tolkoff-Rubin N et al. Prevalence and significance of anti-HLA and donor-specific antibodies long-term after renal transplantation. Transpl Int 2005; 18: 532540.
  • 40
    Lee PC, Terasaki PI, Takemoto SK et al. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 2002; 74: 11921194.
  • 41
    Mengel M, Bogers J, Bosmans JL et al. Incidence of C4d stain in protocol biopsies from renal allografts: results from a multicenter trial. Am J Transpl 2005; 5: 10501056.
  • 42
    Vella JP, Spadafora-Ferreira M, Murphy B et al. Indirect allorecognition of major histocompatibility complex allopeptides in human renal transplant recipients with chronic graft dysfunction. Transplantation 1997; 64: 795800.
  • 43
    Sayegh MH. Why do we reject a graft? Role of indirect allorecognition in graft rejection. Kidney Int 1999; 56: 19671979.
  • 44
    Watschinger B, Pascual M. Capillary C4d deposition as a marker of humoral immunity in renal allograft rejection. J Am Soc Nephrol 2002; 13: 24202423.
  • 45
    Steele DJR, Laufer TM, Smiley ST et al. Two levels of help for B cell alloantibody production. J Exp Med 1996; 183: 699703.
  • 46
    Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 27152729.
  • 47
    Williams JM, Holzknecht ZE, Plummer TB, Lin SS, Brunn GJ, Platt JL. Acute vascular rejection and accommodation: divergent outcomes of the humoral response to organ transplantation. Transplantation 2004; 78: 14711478.
  • 48
    King KE, Warren DS, Samaniego-Picota M, Campbell-Lee S, Montgomery RA, Baldwin WM. Antibody, complement and accommodation in ABO-incompatible transplants. Curr Opin Immunol 2004; 16: 545549.
  • 49
    Ishida H, Tanabe K, Ishizuka T, Furusawa M, Miyamoto N, Ishikawa N. The mechanism responsible for accommodation after living-related kidney transplantations across the blood barrier. Transpl Intern 2005; 18: 716720.
  • 50
    Hammond EH, Yowell RL, Nunoda S et al. Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications. J Heart Transplant 1989; 8: 430443.
  • 51
    Behr TM, Feucht HE, Richter K et al. Detection of humoral rejection in human cardiac allografts by assessing the capillary deposition of complement fragment C4d in endomyocardial biopsies. J Heart Lung Transplant 1999; 18: 904912.
  • 52
    Michaels PJ, Espejo MJ, Kobashigawa J et al. Humoral rejection in cardiac transplantation: risk factors hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant 2003; 22: 5869.
  • 53
    Poelzl G, Ullrich R, Huber A et al. Capillary deposition of the complement fragment C4d in cardiac allograft biopsies is associated with allograft vasculopathy. Transplant Int 2005; 18: 313317.
  • 54
    Subherwal S, Kobashigawa JA, Cogert G, Patel J, Espejo M, Oeser B. Incidence of acute cellular rejection and non-cellular rejection in cardiac transplantation. Transplant Proc 2004; 36: 31713172.
  • 55
    Baldwin WM, Samaniego-Picota M, Kasper EK et al. Complement deposition in early cardiac transplant biopsies is associated with ischemic injury and subsequent rejection episodes. Transplantation 1999; 68: 894900.
  • 56
    Magro CM, Harman AP, Klinger D et al. Use of C4d as a diagnostic adjunct in lung allograft biopsies. Am J Transplant 2003; 3: 11431154.
  • 57
    Magro CM, Klinger DM, Adams PW et al. Evidence that humoral allograft rejection in lung transplant patients is not histocompatibility antigen-related. Am J Transplant 2003; 3: 12641272.
  • 58
    Reznik SI, Jaramillo A, Zhang L, Patterson GA, Cooper JD, Mohanakumar T. Anti-HLA antibody binding to HLA class I molecules induces proliferation of airway epithelial cells: a potential mechanism for bronchiolitis obliterans syndrome. J Thorac Cardiovasc Surg 2000; 119: 3945.
  • 59
    Krukemeyer MG, Moeller J, Morawietz L et al. Description of B lymphocytes and plasma cells, complement, and chemokines/receptors in acute liver allograft rejection. Transplantation 2004; 78: 6570.